Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance to Participate in Upcoming Investor Conferences

Business Wire November 20, 2018

Revance to Participate in the Credit Suisse Healthcare Conference

Business Wire November 7, 2018

Revance Releases Third Quarter 2018 Results

Business Wire November 1, 2018

Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018

Business Wire October 18, 2018

Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals — Discovering Underlying Factors of Influence

GlobeNewswire October 11, 2018

Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer

Business Wire October 11, 2018

Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference

Business Wire September 24, 2018

Revance Receives Great Place to Work Certification

Business Wire September 20, 2018

Revance Releases Second Quarter 2018 Results

Business Wire August 2, 2018

Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018

Business Wire July 19, 2018

Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia

Business Wire June 21, 2018

Revance to Participate in the JMP Securities Life Sciences Conference 2018

Business Wire June 14, 2018

Revance to Participate in Upcoming Investor Conferences

Business Wire June 5, 2018

Revance to Participate in the Jefferies 2018 Global Healthcare Conference

Business Wire May 29, 2018

Revance Announces Departure of Chief Financial Officer

Business Wire May 29, 2018

Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice

Business Wire May 24, 2018

Revance to Participate in the UBS Global Healthcare Conference

Business Wire May 15, 2018

Revance Therapeutics Announces Two Recent Additions to Its Management Team

Business Wire May 9, 2018

Revance Releases First Quarter 2018 Results

Business Wire May 8, 2018

Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary

Business Wire May 1, 2018